Michael Staversky, PA
Physician Assistant · Ladson, SCNPI 1093317646
Payments from drug & device makers
Across 329 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$699
- Novo Nordisk$622
- AstraZeneca$550
- Lilly USA, LLC$384
- Sanofi-aventis U.S. LLC$342
- Pfizer$330
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,163100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $699 |
| Novo Nordisk | 36 | $622 |
| AstraZeneca | 23 | $550 |
| Lilly USA, LLC | 21 | $384 |
| Sanofi-aventis U.S. LLC | 13 | $342 |
| Pfizer | 17 | $330 |
| Amgen | 16 | $293 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $290 |
| Otsuka America Pharmaceutical, Inc. | 13 | $248 |
| Insulet Corporation | 12 | $220 |
| Abbott | 9 | $219 |
| Axsome Therapeutics, Inc. | 10 | $195 |
| Xeris Pharmaceuticals, Inc. | 8 | $149 |
| Vanda Pharmaceuticals Inc. | 5 | $148 |
| GSK | 7 | $139 |
| Novartis | 8 | $132 |
| Dexcom, Inc. | 4 | $120 |
| Exact Sciences | 6 | $107 |
| Boston Scientific | 2 | $82 |
| Boehringer Ingelheim | 5 | $80 |
| Antares Pharma, Inc. | 4 | $76 |
| Astellas Pharma US Inc | 3 | $70 |
| Corcept Therapeutics | 3 | $68 |
| Corium, LLC | 2 | $65 |
| Bayer | 3 | $65 |
| Philips North America LLC | 4 | $58 |
| Merck | 4 | $55 |
| Seqirus USA Inc | 2 | $44 |
| Cequr Corporation | 1 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Gilead | 2 | $34 |
| Organon | 2 | $33 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Ascensia Diabetes Care US Inc. | 1 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$6,169 in reported general payments places this provider in the 90th percentile of 1,852 physician assistant providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 52 | $54,060 |
| JardianceEmpagliflozin | 19 | $28,689 |
| MounjaroTirzepatide | 12 | $26,967 |
| RybelsusSemaglutide | 14 | $25,139 |
| OzempicSemaglutide | 23 | $21,675 |
| EliquisApixaban | 24 | $21,666 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $20,126 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,640 |
| MyrbetriqMirabegron | 12 | $7,713 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,463 |
| Atorvastatin Calcium | 146 | $1,094 |
| Gabapentin | 34 | $552 |
| Omeprazole | 21 | $519 |
| Amlodipine Besylate | 91 | $511 |
| Hydroxyzine Hcl | 20 | $464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $550 | $74,18677 claims |
| Novo NordiskRybelsus, Ozempic | $622 | $46,81437 claims |
| Boehringer IngelheimJardiance | $80 | $28,68919 claims |
| Lilly USA, LLCMounjaro | $384 | $26,96712 claims |
| PfizerEliquis | $330 | $21,66624 claims |
| GSKTrelegy Ellipta | $139 | $13,64011 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $7,71312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,852 physician assistant providers in South Carolina.
Other physician assistant in Ladson
- Benjamin AddyWest Columbia$377K
- Michael OvercashCharleston$210K
- Allison LesterMt Pleasant$163K
- Nicole KeeterFort Mill$129K
- William YoungGreenville$117K
- Stephanie DavisAnderson$78K
- Vicki RobertsWest Columbia$77K
- Eric ShoupColumbia$74K
- Lauren OlsonNorth Charleston$62K
- Martha GreenSummerville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.